KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ginkgo Bioworks Holdings (DNA) EBT (2020 - 2025)

Ginkgo Bioworks Holdings' EBT history spans 6 years, with the latest figure at -$81.4 million for Q4 2025.

  • For Q4 2025, EBT rose 24.54% year-over-year to -$81.4 million; the TTM value through Dec 2025 reached -$313.6 million, up 42.72%, while the annual FY2025 figure was -$313.6 million, 42.72% up from the prior year.
  • EBT reached -$81.4 million in Q4 2025 per DNA's latest filing, down from -$80.8 million in the prior quarter.
  • In the past five years, EBT ranged from a high of -$54.9 million in Q2 2021 to a low of -$1.6 billion in Q4 2021.
  • Average EBT over 5 years is -$285.7 million, with a median of -$169.6 million recorded in 2023.
  • Peak YoY movement for EBT: plummeted 3361.18% in 2021, then soared 88.3% in 2022.
  • A 5-year view of EBT shows it stood at -$1.6 billion in 2021, then skyrocketed by 88.3% to -$187.8 million in 2022, then decreased by 12.8% to -$211.9 million in 2023, then surged by 49.1% to -$107.9 million in 2024, then grew by 24.54% to -$81.4 million in 2025.
  • Per Business Quant, the three most recent readings for DNA's EBT are -$81.4 million (Q4 2025), -$80.8 million (Q3 2025), and -$60.6 million (Q2 2025).